Q2 2025 · 13F-HR
GILEAD SCIENCES, INC. (GILD)holdings as filed
Filed 2025-08-14 · accession 0001123292-25-000364
$1.28B
Reported value
14
Positions
2025-06-30
Period end
The Brief · GILEAD SCIENCES, INC. (GILD) · Q2 2025
AI · grounded in 13F
GILEAD SCIENCES, INC. (GILD) established a new position in Galapagos NV LKFT valued at $467.6M. The fund also initiated new stakes in Arcellx Inc ACLXGBX for $442.6M and Arcus Biosciences Inc RCUS for $255.8M. Additional new positions include Assembly Biosciences Inc ASMB, Tango Therapeutics Inc TNGX, and Merus N V 2GH.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 36315X101 | LKFT | GALAPAGOS NV | $467.6M | 36.5% | 16,707,477 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $442.6M | 34.6% | 6,720,803 | Common | SOLE |
| 03969F109 | RCUS | ARCUS BIOSCIENCES INC | $255.8M | 20.0% | 31,424,760 | Common | SOLE |
| 045396207 | ASMB | ASSEMBLY BIOSCIENCES INC | $40.0M | 3.13% | 2,209,471 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $24.9M | 1.94% | 4,854,443 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $23.8M | 1.86% | 452,527 | Common | SOLE |
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $12.7M | 0.99% | 4,126,119 | Common | SOLE |
| 98422T100 | XLO | XILIO THERAPEUTICS INC | $6.2M | 0.48% | 9,105,451 | Common | SOLE |
| 43906K209 | HOOK | HOOKIPA PHARMA INC | $2.4M | 0.18% | 1,875,945 | Common | SOLE |
| 52187K200 | CYPH | LEAP THERAPEUTICS INC | $1.6M | 0.12% | 5,319,148 | Common | SOLE |
| 019770106 | ALLO | ALLOGENE THERAPEUTICS INC | $1.3M | 0.10% | 1,156,689 | Common | SOLE |
| 482929106 | KLRS | KALARIS THERAPEUTICS INC | $848,497 | 0.07% | 317,789 | Common | SOLE |
| 45175G108 | — | IKENA ONCOLOGY INC | $467,053 | 0.04% | 348,534 | Common | SOLE |
| 91864C107 | BRNS | BARINTHUS BIOTHERAPEUTICS PL | $92,524 | 0.01% | 99,478 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.